Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. The company was founded in 1907 and is headquartered in Vadodara, India.

Revenue projections:

Revenue projections for APLLTD
Revenue projections for APLLTD

With APLLTD's revenue expected to be lower than the previous year, investors may become cautious. Declining revenues often negatively impact the bottom line, reducing profitability and raising concerns among investors about the company's ability to maintain strong financial performance moving forward.

Financial Ratios:

currentRatio 0.00000
forwardPE 16.45595
debtToEquity 28.00400
earningsGrowth -0.03600
revenueGrowth 0.10800
grossMargins 0.71510
operatingMargins 0.11372
trailingEps 32.08000
forwardEps 43.21841

APLLTD's Forward PE is in a reasonable range, indicating the stock is priced well relative to its earnings. The stock isn't overpriced, which leaves room for future growth, making it an attractive option for investors seeking value and long-term gains.
APLLTD's low Debt-to-Equity ratio suggests the company is minimally leveraged, with limited reliance on debt to finance its operations. This reduced financial risk positions the company for greater stability and financial health, appealing to investors who value conservative financial management.
APLLTD's low growth in both earnings and revenue indicates the company's profits may decrease. This trend could signal a downturn in financial performance, suggesting that APLLTD might struggle to maintain its current profit levels.
APLLTD's negative gross and operating margins suggest that the company is struggling to cover its production and operating costs, leading to losses. This reflects a weakened financial state and potential difficulties in sustaining profitability.
APLLTD's forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that APLLTD is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.

Price projections:

Price projections for APLLTD
Price projections for APLLTD

APLLTD's present price, in relation to projections, does not offer clear risks or opportunities. This stable scenario suggests a period of consolidation, where investors might prefer to hold off on significant changes in strategy.

Insider Transactions:

Insider Transactions for APLLTD
Insider Transactions for APLLTD


APLLTD had 20 buy transactions while market price was at 881.7800018310547 per share.No buy transactions took place in the period under consideration.Increased sells at Alembic Pharmaceuticals Limited's current price levels point to a possible decline. If this trend of selling continues, it may signal that the stock's price will face further downward pressure, reflecting investor concerns.

Recommendation changes over time:

Recommendations trend for APLLTD
Recommendations trend for APLLTD


Analysts have been favoring APLLTD with a buy bias recently, signaling a promising investment opportunity. This optimistic outlook may attract more investors, positioning APLLTD as a desirable option for those seeking to invest their money in a stable, profitable company with strong growth potential.